Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
NovaMedica to produce migraine drug Relonova in Moscow
- By Newsdesk
- Moscow
- Mar 23, 2023
NovaMedica, a Rusnano portfolio company in Russia has registered Relonova, a drug used to relieve headaches during migraine attacks. According to the company's press service, this is the first rizatriptan-based drug that has been fully localized in the Russian Federation.
The drug will be manufactured at the NovaMedica Innotech Technology Center in Moscow. The medication will only be available on prescription to adults. Relonova is intended to be used as an emergency pain reliever during migraine attacks. It can also be used in patients with a long history of migraine when other analgesics lose their effectiveness.
According to NovaMedica's press service, Relonova is the fourth drug that the company has developed and registered in the last year. Previously, therapies for dementia and Alzheimer's disease, insomnia, and severe pain were approved for registration.